Recurrent Esophageal Cancer Terminated Phase 1 Trials for Lapatinib (DB01259)

IndicationStatusPhase
DBCOND0028797 (Recurrent Esophageal Cancer)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01705340Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTreatment